Literature DB >> 27070344

Progressive supranuclear palsy (PSP): Richardson syndrome and other PSP variants.

G Lopez1, K Bayulkem2, M Hallett2.   

Abstract

Phenotypic heterogeneity of progressive supranuclear palsy (PSP) has been increasingly reported in the literature and can be the source of incorrect clinical diagnosis particularly in the early stages of the disease when the classically associated symptoms of early falls and supranuclear gaze palsy may not be apparent. In addition to Richardson syndrome (RS), several atypical clinical phenotypes have been described. Advances in genetic, neuroimaging, and biochemical/molecular technologies contribute to the identification of these clinical subtypes in the context of typical PSP pathological findings. Our goal is to review the phenomenology reported in the literature that is associated with confirmed histopathological changes consistent with a PSP diagnosis and to highlight the clinical spectrum of PSP. A systematic review of the literature in PubMed through July 2015 using MeSH terms and key words related to PSP was conducted. Articles describing PSP classifications, diagnostic criteria, and case reports were reviewed and summarized. Additional PSP phenotypes not seen in recent clinicopathological studies are included. These include primary lateral sclerosis, pallido-nigro-luysian degeneration, axonal dystrophy, and multiple system atrophy in the spectrum of atypical PSP variants beyond the traditionally classified PSP subtypes. This review is intended to help with the diagnostic challenges of atypical PSP variants. We believe that large multicenter clinicopathological studies will help expand our understanding of etiology and specific mechanisms of neurodegeneration and will aid in the appropriate interpretation of outcomes when conducting clinical and basic science research. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  Richardson syndrome; atypical parkinsonism; phenomenology; progressive supranuclear palsy; tauopathy

Mesh:

Year:  2016        PMID: 27070344      PMCID: PMC7292631          DOI: 10.1111/ane.12546

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  45 in total

1.  Making sense of progressive non-fluent aphasia: an analysis of conversational speech.

Authors:  Jonathan A Knibb; Anna M Woollams; John R Hodges; Karalyn Patterson
Journal:  Brain       Date:  2009-08-20       Impact factor: 13.501

2.  MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy.

Authors:  C Vilariño-Güell; A I Soto-Ortolaza; A Rajput; D C Mash; S Papapetropoulos; R Pahwa; K E Lyons; R J Uitti; Z K Wszolek; D W Dickson; M J Farrer; O A Ross
Journal:  Neurology       Date:  2011-02-15       Impact factor: 9.910

3.  Genotype-phenotype correlation--promiscuity in the era of next-generation sequencing.

Authors:  James T Lu; Philippe M Campeau; Brendan H Lee
Journal:  N Engl J Med       Date:  2014-08-14       Impact factor: 91.245

4.  Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy.

Authors:  Dominique Caparros-Lefebvre; Nicolas Sergeant; Andrew Lees; Agnes Camuzat; Susan Daniel; Annie Lannuzel; Alexis Brice; Eduardo Tolosa; Andre Delacourte; Charles Duyckaerts
Journal:  Brain       Date:  2002-04       Impact factor: 13.501

5.  Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases.

Authors:  F Piccione; E Mancini; P Tonin; M Bizzarini
Journal:  Arch Phys Med Rehabil       Date:  1997-05       Impact factor: 3.966

Review 6.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.

Authors:  I Litvan; Y Agid; D Calne; G Campbell; B Dubois; R C Duvoisin; C G Goetz; L I Golbe; J Grafman; J H Growdon; M Hallett; J Jankovic; N P Quinn; E Tolosa; D S Zee
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

Review 7.  Frontotemporal lobar degeneration: a clinical approach.

Authors:  Elissaios Karageorgiou; Bruce L Miller
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

Review 8.  Progressive supranuclear palsy.

Authors:  Lawrence I Golbe
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

9.  Progressive supranuclear palsy in a family with TDP-43 pathology.

Authors:  A Kertesz; E Finger; J Murrell; H Chertkow; L C Ang; M Baker; T Ravenscroft; R Rademakers; D G Munoz
Journal:  Neurocase       Date:  2014-01-30       Impact factor: 0.881

Review 10.  Neuropathological background of phenotypical variability in frontotemporal dementia.

Authors:  Keith A Josephs; John R Hodges; Julie S Snowden; Ian R Mackenzie; Manuela Neumann; David M Mann; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2011-05-26       Impact factor: 17.088

View more
  14 in total

1.  Clinical Reasoning: A 58-year-old man with progressive ptosis and walking difficulty.

Authors:  Pei-Hsin Kuo; Raymond Y Lo; Kurenai Tanji; Sheng-Han Kuo
Journal:  Neurology       Date:  2017-07-04       Impact factor: 9.910

Review 2.  Emerging Diagnostic and Therapeutic Strategies for Tauopathies.

Authors:  David Coughlin; David J Irwin
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09       Impact factor: 5.081

Review 3.  "Parkinson's disease" on the way to progressive supranuclear palsy: a review on PSP-parkinsonism.

Authors:  Ján Necpál; Miroslav Borsek; Bibiána Jeleňová
Journal:  Neurol Sci       Date:  2021-09-17       Impact factor: 3.307

4.  Training high level balance and stepping responses in atypical progressive supranuclear palsy: a case report.

Authors:  Earllaine Croarkin; Krystle Robinson; Christopher J Stanley; Cris Zampieri
Journal:  Physiother Theory Pract       Date:  2022-01-29       Impact factor: 2.176

5.  Progressive Supranuclear Palsy: Improvement in Cognitive-Behavioral Disturbances and Motor-Function Disabilities Following Treatment With Antidepressants and Cholinesterase Inhibitors.

Authors:  Michelle Oyeka; Terngu Ibilah; Jacob Israel; Jose Gavito-Higuera; Ricardo Salazar
Journal:  Cureus       Date:  2021-06-14

Review 6.  Axonal Degeneration during Aging and Its Functional Role in Neurodegenerative Disorders.

Authors:  Natalia Salvadores; Mario Sanhueza; Patricio Manque; Felipe A Court
Journal:  Front Neurosci       Date:  2017-09-04       Impact factor: 4.677

Review 7.  How to spot ocular abnormalities in progressive supranuclear palsy? A practical review.

Authors:  Onanong Phokaewvarangkul; Roongroj Bhidayasiri
Journal:  Transl Neurodegener       Date:  2019-07-10       Impact factor: 8.014

8.  Phenotypic Variants of Patients with Progressive Supranuclear Palsy.

Authors:  Murat Gültekın
Journal:  Noro Psikiyatr Ars       Date:  2017-11-08       Impact factor: 1.339

Review 9.  Language impairment in progressive supranuclear palsy and corticobasal syndrome.

Authors:  Katie A Peterson; Karalyn Patterson; James B Rowe
Journal:  J Neurol       Date:  2019-07-18       Impact factor: 4.849

10.  Brain gray matter abnormalities in progressive supranuclear palsy revisited.

Authors:  PingLei Pan; Yi Liu; Yang Zhang; Hui Zhao; Xing Ye; Yun Xu
Journal:  Oncotarget       Date:  2017-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.